Investor Presentaiton

Phase 1/2a Trial: Patients Trial opened in June 2020 • 19 patients enrolled as of August 2022 95% of patients have non-G12C mutations Cohort is heavily treated - all patients progressed on prior PD1/L1 inhibitors 280mg BID 560mg AM 280mg PM 560mg BID Expansion Phase Baseline Characteristics Age in years - median (range) Type of KRAS mutation – n (%) - Cohort N=19 65 (45-80) G12V 7 (37%) G12D 5 (26%) G12C 1 (5%) G12F 1 (5%) G12A 1 (5%) G13 (D/C) 2 (11%) Other (Q61H, 146T) 2 (11%) STK11 Co-mutations 5 (26%) PDL1 Expression - n (%) 50% 4 (21%) 1-49% 7 (37%) <1% 8 (42%) Smoking history - n (%) Current/Former 15 (79%) Never 4 (21%) Prior Lines of Systemic Therapy – n (%) - 1 3 (20%) 2 9 (60%) 3 (20%) Adapted from Veluswamy et al. European Society for Medical Oncology Congress 2022. ≥ 3 ONCONOVA THERAPEUTICS

View entire presentation